RS55459B1 - Modulatori farmakokinetičkih svojstava lekova - Google Patents
Modulatori farmakokinetičkih svojstava lekovaInfo
- Publication number
- RS55459B1 RS55459B1 RS20160992A RSP20160992A RS55459B1 RS 55459 B1 RS55459 B1 RS 55459B1 RS 20160992 A RS20160992 A RS 20160992A RS P20160992 A RSP20160992 A RS P20160992A RS 55459 B1 RS55459 B1 RS 55459B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- atazanavir
- formula
- iibb
- formula iibb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Farmaceutska kompozicija koja sadrži jedinjenje formule IIB:
ili farmaceutski prihvatljiva so, solvat, stereoizomer i/ili ester od njega, pri čemu: R103i<R10b>su svaki nezavisno H ili -cM alkil; Ru je H ili -CH3; R" je -(CH2jVjCR17R18NR20R", -(CH2)wCR<17>R<18>NR'<7>C(0) NR<m>R<21>, -(CH2),.3C(0)R*2, -(CH2),.3S(0)2R<22>ili -(CHOio-R23; RH i R<15>su svaki nezavisno H, -Cm alkil ili arilalkil; R17 i R<18>su svaki nezavisno H ili -Ci 3 alkil; Rl* je H, -Cmalkil ili arilalkil;R20i R<21>su svaki nezavisno H, -C-jalkil, -C(0)R17 ili -S(0)2R<17>;ili R20 i R<21>, uzeti zajedno sa atomom azota za koji su vezani, formiraju nesupstituisani ili supstituisani 5-6 člani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i 0; R22 je H, -CH alkil, -OR19ili -NR<20>R21;iRJ3 nesupstituisani ili supstituisani 5-6-Člani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i 0;
pi čemu je navedeni nesupstituisani ili supstituisani petočlani-šestočlani član heterociklični prsten formiran od R<20>i R<21>i navedeni nesupstituisani ili supstituisani petočlani-šestočlani heterociklični prsten od R<23>su svaki nezavisno nesupstituisani ili supstituisani sa C|.2alkilom, farmaceutski prihvatljivim nosačem ili pomoćnim sredstvom-ekscipijentom i atazanavirom ili farmaceutski prihvatljivom soli, solvatom i/ili estrom od njih.
2.Farmaceutska kompozicija prema patentnom zahtevu 1, koja sadrži jedinjenje formule IIB, ili farmaceutski prihvatljivu so, solvat, stereoizomer i/ili estar od njih, pri čemu R<u>je -(CH;V3CR1''RiaNRMR2', - (CH2)0.3CR<17>R<l8>NR<l7>C(O) NR<20>R<21>ili -(CH2),.3-R<23>.
3.Farmaceutska kompozicija prema patentnom zahtevu 2, koja sadrži jedinjenje formule IIB, ili farmaceutski prihvatljivu so, solvat, stereoizomer i/ili estar od njih, pri čemu R<n>je-(CHj)o.jCR,<7>R<18>NR<20>R21 ili-(CH2y3 CR17R18NR17C(O)-NR20R21.
4.Farmaceutska kompozicija prema patentnom zahtevu 1 pri čemu jedinjenje formule IIB je jedinjenje formule IIC:
ili farmaceutski prihvatljiva so, solvat, stereoizomer i/ili ester od njega, pri čemu: R13 je -(CHO0.3- CR1ZR1SNR20R21, -(CH2)W CR<l7>R18NR<i;>C(0) NR<20>R<21>, -(CH2),.3C(0)R<22>ili -(CHO^-R23; R17 i R<18>su svaki nezavisno H ili C,-3 alkil; RI9je H, -Cm alkil ili arilalkil; R20 i R<2!>su svaki nezavisno H, -d-salkil, -C(0)R<1?>i!i-S(0)2R17; ili R<20>i R<21>, uzeti zajedno sa atomom azota za koji su vezani, formiraju petočlani-šestočlani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i 0; R22 je H, -Ci-3alkil, -OR19ili -NR<20>R:i;i R23 je nesupstituisani ili supstituisani petočlani-šestočlani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i 0;
5.Farmaceutska kompozicija prema patentnom zahtevu 1 pri čemu je jedinjenje formule IIB jedinjenje formule IIBa:
ili farmaceutski prihvatljiva so, solvat, i/ili ester od njega.
6.Farmaceutska kompozicija prema patentnom zahtevu 5, pri čemu jedinjenje formule IIB je jedinjenje formule IIBb:
ili farmaceutski prihvatljiva so, solvat, i/ili ester od njega.
7.Farmaceutska kompozicija prema zahtevu 6, koja sadrži kombinaciju izabranu od: jedinjenje formule IIBb/tenofovir dizoproksil fumarat/atazanavir, jedinjenje formule IIBb/GS-913 l/atazanavir, jedinjenje formule IIBb/emtricitabin/atazanavir, jedinjenje formule IIBb/elvitegravir/atazanavir, jedinjenje formule IIBb/efavirenz/atazanavir, jedinjenje formule IIBb/atazanavir/raltegravir, i jedinjenje formule IIBb/atazanavir/rilpivirin.
8.Farmaceutska kompozicija prema zahtevu 6, koja sadrži kombinaciju izabranu od: jedinjenje formule IIBb/tenofovir dizoproksil fumarat/GS-9131/atazanavir, jedinjenje formule IIBb/tenofovir dizoproksil fumarat/emtricitabin/ atazanavir, jedinjenje formule IIBb/tenofovir dizoproksil fumarat/elvitagravir/atazanavir, jedinjenje formule IIBb/tenofovir dizoproksil fumarat/efavirenz/atazanavir, jedinjenje formule IIBb/tenofovir dizoproksil fumarat/atazanavir/raltegravir, jedinjenje formule IIBb/tenofovir dizoproksil fumarat/atazanavir/rilpivirin, jedinjenje formule IIBb/GS-9131/emtricitabin/atazanavir, jedinjenje formule IIBb/GS-9131/elvitegravir/atazanavir, jedinjenje formule IIBb/GS-9131/efavirenz/atazanavir, jedinjenje formule IIBb/GS-9131/atazanavir/raltegravir, jedinjenje formule IIBb/GS-9131/atazanavir/rilpivirine, jedinjenje formule IIBb/emtricitabin/elvitegravir/atazanavir, jedinjenje formule IIBb/emtricitabin/efavirenz/atazanavir, jedinjenje formule IIBb/emtricitabin/atazanavir/raltegravir, jedinjenje formule IIBb/emtricitabin/atazanavir/rilpivirin, jedinjenje formule IIBb/elvitegravir/efavirenz/atazanavir, jedinjenje formule IIBb/elvitegravir/atazanavir/raltegravir, jedinjenje formule IIBb/elvitegravir/atazanavir/rilpivirin, jedinjenje formule IIBb/efavirenz/atazanavir/raltegravir, i jedinjenje formule IIBb/efavirenz/atazanavir/rilpivirin.
9.Farmaceutska kompozicija prema patentnom zahtevu 7, koja sadrži kombinaciju jedinjenja formule IIBb/tenofovir dizoproksil fumarat/atazanavir.
10.Farmaceutska kompozicija prema patentnom zahtevu7,koja sadrži kombinaciju jedinjenja formule IIBb/emtricttabin/atazanavir.
11.Farmaceutska kompozicija prema patentnom zahtevu 8, pri ;emu kompozicija sadrži kombinaciju jedinjenja formulellBb/tenofovir dizoproksil fumarat/emtricitabin/atazanavir.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90322807P | 2007-02-23 | 2007-02-23 | |
| US95871607P | 2007-07-06 | 2007-07-06 | |
| EP12167591.2A EP2487163B1 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55459B1 true RS55459B1 (sr) | 2017-04-28 |
Family
ID=46465350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160889A RS55195B1 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava terapeutika |
| RS20160857A RS55351B2 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava lekova |
| RS20160992A RS55459B1 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava lekova |
| RS20160883A RS55280B1 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava lekova |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160889A RS55195B1 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava terapeutika |
| RS20160857A RS55351B2 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava lekova |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160883A RS55280B1 (sr) | 2007-02-23 | 2008-02-22 | Modulatori farmakokinetičkih svojstava lekova |
Country Status (8)
| Country | Link |
|---|---|
| EP (6) | EP2487166B1 (sr) |
| DK (3) | DK2487163T3 (sr) |
| HU (2) | HUS1600052I1 (sr) |
| ME (4) | ME02628B (sr) |
| PL (2) | PL2487163T3 (sr) |
| RS (4) | RS55195B1 (sr) |
| SI (4) | SI2487161T2 (sr) |
| UA (1) | UA101312C2 (sr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860995A1 (en) * | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| PT1183026E (pt) | 1999-06-04 | 2006-11-30 | Abbott Lab | Formulações farmacêuticas melhoradas incluindo ritonavir |
| KR101477822B1 (ko) | 2006-07-07 | 2015-01-02 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학 특성의 모듈레이터 |
| PT3150586T (pt) | 2007-02-23 | 2020-03-31 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
-
2008
- 2008-02-22 ME MEP-2016-260A patent/ME02628B/me unknown
- 2008-02-22 RS RS20160889A patent/RS55195B1/sr unknown
- 2008-02-22 PL PL12167591T patent/PL2487163T3/pl unknown
- 2008-02-22 SI SI200831700T patent/SI2487161T2/sl unknown
- 2008-02-22 SI SI200831693A patent/SI2487163T1/sl unknown
- 2008-02-22 RS RS20160857A patent/RS55351B2/sr unknown
- 2008-02-22 DK DK12167591.2T patent/DK2487163T3/en active
- 2008-02-22 SI SI200831691A patent/SI2487166T1/sl unknown
- 2008-02-22 SI SI200831705A patent/SI2487162T1/sl unknown
- 2008-02-22 EP EP12167596.1A patent/EP2487166B1/en not_active Revoked
- 2008-02-22 EP EP12167591.2A patent/EP2487163B1/en not_active Revoked
- 2008-02-22 ME MEP-2016-262A patent/ME02680B/me unknown
- 2008-02-22 PL PL12167596T patent/PL2487166T3/pl unknown
- 2008-02-22 ME MEP-2016-241A patent/ME02582B/me unknown
- 2008-02-22 EP EP20120167597 patent/EP2487167A1/en not_active Withdrawn
- 2008-02-22 UA UAA200909677A patent/UA101312C2/ru unknown
- 2008-02-22 DK DK12167590.4T patent/DK2487162T3/en active
- 2008-02-22 ME MEP-2016-263A patent/ME02631B/me unknown
- 2008-02-22 EP EP12167590.4A patent/EP2487162B1/en not_active Revoked
- 2008-02-22 RS RS20160992A patent/RS55459B1/sr unknown
- 2008-02-22 EP EP20120167599 patent/EP2487168A1/en not_active Withdrawn
- 2008-02-22 DK DK12167589.6T patent/DK2487161T4/da active
- 2008-02-22 RS RS20160883A patent/RS55280B1/sr unknown
- 2008-02-22 EP EP20120167593 patent/EP2487164A1/en not_active Withdrawn
-
2016
- 2016-12-12 HU HUS1600052C patent/HUS1600052I1/hu unknown
- 2016-12-12 HU HUS1600053C patent/HUS1600053I1/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2487161T1 (sl) | 2016-12-30 |
| HUS1600053I1 (hu) | 2017-01-30 |
| EP2487162B1 (en) | 2016-08-17 |
| ME02628B (me) | 2017-06-20 |
| ME02631B (me) | 2017-06-20 |
| DK2487161T3 (en) | 2016-10-24 |
| DK2487163T3 (en) | 2016-10-24 |
| EP2487166B1 (en) | 2016-07-27 |
| RS55195B1 (sr) | 2017-01-31 |
| UA101312C2 (ru) | 2013-03-25 |
| DK2487161T4 (da) | 2024-06-24 |
| ME02582B (me) | 2017-06-20 |
| PL2487166T3 (pl) | 2017-07-31 |
| RS55351B1 (sr) | 2017-03-31 |
| EP2487168A1 (en) | 2012-08-15 |
| HUS1600052I1 (hu) | 2017-01-30 |
| ME02680B (me) | 2017-06-20 |
| SI2487162T1 (sl) | 2016-12-30 |
| DK2487162T3 (en) | 2016-10-24 |
| PL2487163T3 (pl) | 2017-04-28 |
| EP2487163B1 (en) | 2016-08-17 |
| SI2487163T1 (sl) | 2016-12-30 |
| SI2487166T1 (sl) | 2017-02-28 |
| EP2487162A1 (en) | 2012-08-15 |
| RS55351B2 (sr) | 2024-09-30 |
| RS55280B1 (sr) | 2017-03-31 |
| EP2487167A1 (en) | 2012-08-15 |
| SI2487161T2 (sl) | 2024-07-31 |
| EP2487163A1 (en) | 2012-08-15 |
| EP2487164A1 (en) | 2012-08-15 |
| EP2487166A1 (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161428T1 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| HRP20150744T2 (hr) | Modulatori farmakokinetiäśkih svojstava lijekova | |
| HRP20241590T1 (hr) | Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2010524932A5 (sr) | ||
| JP2020509022A5 (sr) | ||
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| WO2007103456A3 (en) | Piperazine and piperidine biaryl derivatives | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| EP2900269A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| JP2014530881A5 (sr) | ||
| EP4606427A3 (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| WO2008046087A3 (en) | Spiro compounds and their uses as therapeutic agents | |
| WO2009066315A3 (en) | Sustained release compositions of trimetazidine and process for preparation thereof | |
| HRP20140151T1 (hr) | Derivati spiro-indola za lijeäśenje parazitnih bolesti | |
| RU2019138248A (ru) | Фармацевтическая композиция для перорального введения, содержащая энзалутамид | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| WO2009140341A3 (en) | Atorvastatin compositions | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| CN109790145A (zh) | 二氢嘧啶类化合物及其制备方法和用途 | |
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| ME02608B (me) | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska | |
| MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
| HRP20151340T1 (hr) | Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije |